Literature DB >> 20556522

Role of systematic lymphadenectomy and adjuvant radiation in early-stage endometrioid uterine cancer.

Nan-Hee Jeong1, Jong-Min Lee, Jae-Kwan Lee, Mi-Kyung Kim, Young-Jae Kim, Chi-Heum Cho, Seok-Mo Kim, Sang-Yoon Park, Chan-Yong Park, Ki-Tae Kim.   

Abstract

OBJECTIVE: To determine the roles of lymphadenectomy in endometrioid uterine cancer patients and adjuvant radiation in early-stage endometrioid uterine cancer patients who underwent systematic lymphadenectomy.
METHODS: A retrospective analysis of 758 patients surgically treated for early-stage endometrioid uterine cancer from 2000 to 2006 was conducted. The primary outcome was 5-year overall survival in relation to systematic lymphadenectomy with or without adjuvant radiation.
RESULTS: Of the 758 patients, 547 (72.2%) underwent complete surgical staging, including systematic lymphadenectomy; adjuvant radiation was administered to 207 patients (27.3%). Within median follow-up of 35 months, systematic lymphadenectomy did not affect overall survival in early-stage patients (P = 0.4480). In the high-risk, early-stage group, however, the 5-year survival rate of the systematic lymphadenectomy group showed better survival compared with the no systematic lymphadenectomy group (P = 0.0095). Also, adjuvant radiation did not affect overall survival in early-stage patients (P = 0.1170), even in the group of high-risk, early-stage patients (P = 0.5680) who underwent systematic lymphadenectomy.
CONCLUSIONS: Systematic lymphadenectomy provided a survival benefit in high-risk endometrioid uterine cancer patients. However, in patients who underwent systematic lymphadenectomy, adjuvant radiation was not beneficial, even in high-risk patients.

Entities:  

Mesh:

Year:  2010        PMID: 20556522     DOI: 10.1245/s10434-010-1169-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Therapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review.

Authors:  Mei-Yi Li; Xiao-Xia Hu; Jian-Hong Zhong; Lu-Lu Chen; Yong-Xiu Lin
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.